Aurinia Pharmaceuticals Inc. Stock News

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at ASN Kidney Week 2024.

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the para...

Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets. AUR200, now in Phase 1 trials, could be a significant future value driver targe...

Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. AUPH is developing AUR200, with a phase 1 trial underway allowing it to diversify beyond Lupkynis. The Company reported a $722K net income for Q2'24, up from a $10.7M net loss in Q1'24.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference.

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Joseph Schwartz - Leerink Partners Stacy Ku - TD Cowen Ed Arce - H.C. Wainwright & Co. Op...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024.